Neoplasms Clinical Trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 188 clinical trials
A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma
The radioisotope Lutetium-177 may be more suitable for radioimmunotherapy than the radioisotopes that have previously been used for non-Hodgkin lymphoma. The Betalutin® binds to an area on the surface of the cancer cells called CD37. This therapy is intended to target the cancer cells with the radioactivity, thereby irradiating them …
- 0 views
- 19 Feb, 2024
- 1 location
A prospective multi-center investigational study of IMMray
Brief Summary: PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care imaging.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 14419: A Phase 1 First in Human Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 17418: A Phase 2b Open-Label Single Arm Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Standard Induction Therapy
The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 19418: A Phase 1/2a Dose-Finding Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 3 Randomized 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis
Brief Summary: The primary objectives of the study by study part are: Part A: To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures, and to inform/confirm the final sample size …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 43419: Prospective Study of Immune Biomarkers in Patients with Multiple Myeloma
The objective of this exploratory observational cohort study is to obtain blood samples - and in some cases, bone marrow aspirate samples - from patients with multiple myeloma for study in the laboratory.
- 0 views
- 19 Feb, 2024
- 1 location
Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
- 0 views
- 19 Feb, 2024
- 1 location